Group I p21-activated kinase (PAK) inhibitor (IC50
= 2.5 μ
M at PAK1). Targets the autoregulatory mechanism and promotes the inactive conformation of PAKs. Inhibits PAK1-mediated signaling in vivo
; potential anti-tumor agent. Negative control PIR 3.5
(Cat. No. 4212) available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Other Product-Specific Information:
An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.
Deacon et al.
Membrane transport of WAVE2 and lamellipodia formation require Pak1 that mediates phosphorylation and recruitment of stathmin/op18 to Pak1-WAVE2-kinesin complex.
Takahashi and Suzuki
An allosteric kinase inhibitor binds the p21-activated kinase (Pak) autoregulatory domain covalently.
Viaud and Peterson
Mol.Cancer Ther., 2009;8:2559
p21-activated kinases in cancer.
Kumar et al.
P21-activated kinase inhibitors FRAX486 and IPA3: inhibition of prostate stromal cell growth and effects on smooth muscle contraction in the human prostate.
Wang et al.
PLoS One, 2016;11:e0153312
The citations listed below are publications that use Tocris products. Selected citations for IPA 3 include:
Showing Results 1 - 10 of 15